HPS Pharmacies wish to advise that Novo Nordisk is experiencing a supply interruption for Ozempic® as follows:


Ozempic® 0.25/0.5mg Pen

Semaglutide 1.34mg/mL

ARTG 308324


Ozempic® 1mg Pen

Semaglutide 1.34mg/mL

ARTG 315107


This supply interruption is due to an unexpected increase in demand. Normal supplies are expected to return by 20 June 2022. An internationally registered brand of semaglutide 0.25mg pens and semaglutide 1mg pens has been approved for supply under Section 19A of the Therapeutic Goods Act 1989.


Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.


Should you require further information regarding this matter, please contact Novo Nordisk on 1800 668 626 or your pharmacist at HPS Pharmacies.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates